New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.

New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.

Curr Opin Pulm Med. 2019 Mar 06;:

Authors: Lee SFK, Laughon BE, McHugh TD, Lipman M

Abstract
PURPOSE OF REVIEW: Treatment of drug-sensitive tuberculosis (TB) is effective, whereas that of multidrug-resistant and extensively drug-resistant TB as well as nontuberculous mycobacterial (NTM) disease are less so. Therapy in general requires good adherence to potentially toxic drug regimens over prolonged periods. Poor adherence is associated with resistance development and poor outcome. This review will present promising new treatments, both new drugs and regimens, for difficult mycobacterial pulmonary infections.
RECENT FINDINGS: A number of new and repurposed drugs including bedaquiline, delamanid, pretomanid, linezolid and clofazimine, and drug regimens, such as the The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (STREAM) trial regimens, are currently progressing from basic research through clinical trials.
SUMMARY:

PMID: 30865034 [PubMed - as supplied by publisher]